Form 4: Viking Therapeutics Director Acquires 18,800 Stock Options

Sarah Kathryn Rouan, a director at Viking Therapeutics, acquired 18,800 stock options on January 2, 2025.

Summary

• Sarah Kathryn Rouan, a director of Viking Therapeutics, acquired 18,800 stock options on January 2, 2025.
• The options have an exercise price of $41.12.
• The options become exercisable on January 2, 2026, and expire on January 2, 2035.
• The transaction was reported on a Form 4 filing with the SEC.

Sentiment

Score: 6

Explanation: The document is a routine SEC filing of a stock option grant to a director. It is neither particularly positive nor negative, but indicates a standard practice of incentivizing directors.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC filing for insider transactions, common in publicly traded companies.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies as part of their compensation and incentive programs.
• The terms of these options, such as the exercise price, vesting period, and expiration date, are generally consistent with industry standards for executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director may be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, Viking Therapeutics, director, insider trading, SEC Form 4, equity